

UCLA

UCLA Previously Published Works

Title

Trends, Predictors, and Outcomes of 30-Day Readmission With Heart Failure After Transcatheter Aortic Valve Replacement: Insights From the US Nationwide Readmission Database

Permalink

<https://escholarship.org/uc/item/4ng4642h>

Journal

Journal of the American Heart Association, 11(16)

ISSN

2047-9980

Authors

Zahid, Salman
Din, Mian Tanveer Ud
Khan, Muhammad Zia
[et al.](#)

Publication Date

2022-08-16

DOI

10.1161/jaha.121.024890









Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives License, available at <https://creativecommons.org/licenses/by-nc-nd/4.0/>

Peer reviewed

ORIGINAL RESEARCH

Trends, Predictors, and Outcomes of 30-Day Readmission With Heart Failure After Transcatheter Aortic Valve Replacement: Insights From the US Nationwide Readmission Database

Salman Zahid , MD; Mian Tanveer Ud Din, MD; Muhammad Zia Khan , MD, MS; Devesh Rai , MD; Waqas Ullah , MD; Alejandro Sanchez-Nadales, MD; Ahmed Elkhapery, MD; Muhammad Usman Khan , MD; Andrew M. Goldsweig , MD, MS; Atul Singla, MD; Greg Fonarow , MD; Sudarshan Balla , MD

BACKGROUND: Data on trends, predictors, and outcomes of heart failure (HF) readmissions after transcatheter aortic valve replacement (TAVR) remain limited. Moreover, the relationship between hospital TAVR discharge volume and HF readmission outcomes has not been established.

METHODS AND RESULTS: The Nationwide Readmission Database was used to identify 30-day readmissions for HF after TAVR from October 1, 2015, to November 30, 2018, using *International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)* codes. A total of 167 345 weighted discharges following TAVR were identified. The all-cause readmission rate within 30 days of discharge was 11.4% (19 016). Of all the causes of 30-day rehospitalizations, HF comprised 31.4% (5962) of all causes. The 30-day readmission rate for HF did not show a significant decline during the study period ($P_{\text{trend}}=0.06$); however, all-cause readmission rates decreased significantly ($P_{\text{trend}}=0.03$). HF readmissions were comparable between high- and low-volume TAVR centers. Charlson Comorbidity Index >8 , length of stay >4 days during the index hospitalization, chronic obstructive pulmonary disease, atrial fibrillation, chronic HF, preexisting pacemaker, complete heart block during index hospitalization, paravalvular regurgitation, chronic kidney disease, and end-stage renal disease were independent predictors of 30-day HF readmission after TAVR. HF readmissions were associated with higher mortality rates when compared with non-HF readmissions (4.9% versus 3.3%; $P<0.01$). Each HF readmission within 30 days was associated with an average increased cost of \$13 000 more than for each non-HF readmission.

CONCLUSIONS: During the study period from 2015 to 2018, 30-day HF readmissions after TAVR remained steady despite all-cause readmissions decreasing significantly. All-cause readmission mortality and HF readmission mortality also showed a nonsignificant downtrend. HF readmissions were comparable across low-, medium-, and high-volume TAVR centers. HF readmission was associated with increased mortality and resource use attributed to the increased costs of care compared with non-HF readmission. Further studies are needed to identify strategies to decrease the burden of HF readmissions and related mortality after TAVR.

Key Words: heart failure ■ TAVI ■ TAVR ■ transcatheter aortic valve implantation ■ transcatheter aortic valve replacement

Correspondence to: Sudarshan Balla, MD, Cardiovascular Disease Fellowship, West Virginia University, Morgantown, WV. Email: sudarshan.balla@wvumedicine.org

Supplemental Material is available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.121.024890>

For Sources of Funding and Disclosures, see page 13.

© 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](#) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

JAHA is available at: www.ahajournals.org/journal/jaha

CLINICAL PERSPECTIVE

What Is New?

- At 30 days after transcatheter aortic valve replacement, 1 in 3 readmissions is attributed to heart failure and is associated with higher readmission mortality rates compared with non-heart failure readmission.

What Are the Clinical Implications?

- High comorbidity burden, length of stay >4 days during the index hospitalization, anemia, atrial fibrillation, paravalvular regurgitation, history of heart failure, preexisting pacemaker, complete heart block during the index hospitalization, chronic kidney disease, and end-stage renal disease are predictors of 30-day heart failure readmission.

Nonstandard Abbreviations and Acronyms

NRD	Nationwide Readmission Database
PPM	preexisting permanent pacemaker
TAVR	transcatheter aortic valve replacement

Since the first-in-human use of transcatheter aortic valve replacement (TAVR) in 2002, TAVR has emerged as the treatment of choice for severe aortic stenosis across the spectrum of surgical risk.¹⁻³ With the rapid advancements in device technology, expansion to lower risk patient groups, increased operator volume, and site experience, TAVR outcomes, including readmission rates, have improved significantly in recent years.^{4,5} Although noncardiac readmissions after TAVR are more common, among cardiac causes of readmissions, heart failure (HF) remains one of the most common culprits.^{6,7}

HF readmissions after TAVR have been associated with significant mortality, morbidity, and health system resource use.^{7,8} Although all-cause readmission rates after TAVR have decreased, the trend of HF readmission has not been established.^{5,6} Similarly, previous studies have reported that increased site TAVR volume may be associated with decreased operative mortality and reduced all-cause unplanned readmission rates.^{9,10} However, the impact of TAVR volume on HF rehospitalizations remains to be explored.

Given the scarcity of data on trends, outcomes, and predictors of HF readmissions, we aimed to study 30-day hospital readmissions for HF after TAVR from a large contemporary data set, the Nationwide Readmission Database (NRD).

METHODS

NRD data are publicly available. The specific data supporting this study's findings are available from the corresponding author upon request.

Study Data

The NRD is sponsored by the Agency for Healthcare Research and Quality and developed through the Federal-State Industry partnership. The database was developed for the HCUP (Healthcare Cost and Utilization Project), and house data on 35 million annual weighted discharges. The discharge data available from 28 states represent 59.7% of the US population and 58.7% of inpatient hospitalizations. The NRD is an all-payer database that captures all admissions and readmissions with nationally representative weighting, allowing the analysis of causes for readmissions and resource use in terms of cost of care. Each patient is assigned a unique identifier code for tracing readmissions within a calendar year. The NRD days-to-event variable captures readmissions within a calendar year but not across different years.¹¹ Given the deidentified nature of the database, institutional review board approval and informed consent were not required for this study.

Study Design and Data Selection

For the study, *International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)* codes were used to identify patients undergoing TAVR (ICD-10-CM code 02RF3x) from October 1, 2015, to November 30, 2018 (Table S1). The discharge weights provided by the NRD were used to provide nationally representative data. The NRD contains data on total hospital charges, which is the amount billed by the hospital. However, charges differ from the actual cost, including the total expense of hospital services, counting utilities, wages, and supplies. To calculate the cost, HCUP provides cost-to-charge ratio files that provide hospital-specific ratios or weighted average ratios to supplement the original NRD file. The cost information was obtained from accounting reports of the participating hospitals collected by the Centers for Medicare and Medicaid Services, with the imputation of missing values when necessary.¹² The cost data on readmission were missing for 61 cases and were not included in the cost calculation. We determined the adjusted cost of care by multiplying the element of the total charge provided by the NRD by the cost-to-charge ratios. We also adjusted hospitalization costs for inflation to January 2020 US dollars using the Bureau of Labor Statistics Consumer Price Index.¹³ A detailed flowchart of the study methods is shown in Figure 1.




Figure 1. Study flow diagram.

Reported numbers are based on weighted hospitalizations. HF indicates heart failure; NRD, Nationwide Readmission Database; and TAVR, transcatheter aortic valve replacement.

Study Definitions

Index admissions were defined for patients undergoing TAVR and discharged alive with no missing variables critical for identifying readmissions (ie, length of stay [LOS], mortality, or days-to-event variables). Index admissions were identified per calendar year from January to November, where December admissions were excluded to allow for analysis of 30-day readmission data. We further excluded patients who left against medical advice or who were transferred to a rehabilitation facility. Readmission was defined as emergent nonelective or elective readmissions within 30 days of discharge. In patients who had multiple 30-day hospitalizations, only the first hospitalization was included in the analysis. Readmission mortality was defined as any death occurring in the hospital within 30 days of discharge (excluding deaths occurring outside the hospital and in the emergency department). HF readmission was defined as unplanned emergent readmission for acute HF. Readmissions for elective causes with a secondary diagnosis of HF were categorized as non-HF readmissions. Based on a prior publication, cutoffs were prespecified, and hospitals performing <50 procedures were categorized as low-volume TAVR centers, 51 to 100 procedures were considered medium-volume centers, and hospitals performing >100 procedures were categorized as high-volume centers.¹⁰

Study End Point

The primary outcome was 30-day readmissions for HF after TAVR discharge. Secondary outcomes included predictors of HF readmissions, temporal trends, in-hospital complications related to HF readmissions compared with non-HF readmissions, the association of readmissions with hospital TAVR discharge volume, and resource use in terms of adjusted hospitalization cost for HF readmissions and non-HF readmissions.

Statistical Analysis

Categorical variables were presented as frequencies and percentages, and continuous variables were reported as medians with an interquartile range (IQR). The Shapiro–Wilk test was used to assess the normality of continuous data. Baseline characteristics were compared using the Pearson χ^2 and Fisher exact tests for categorical variables and the Mann–Whitney *U* and Kruskal–Wallis tests for continuous variables. The *P* value for the slope was used to assess temporal trends. A multivariable logistic regression model was developed to compute independent predictors of 30-day HF readmission by using the enter regression method. The index hospitalization characteristics of patients readmitted with HF were compared with those who were not readmitted. From the index

hospitalization group, we excluded index cases that were readmitted for non-HF causes. Baseline variables that were nonsignificant on univariate analysis ($P>0.05$) and variables with <10 observations were excluded. As the overall missing values were minimal, we used listwise deletion and did not include missing values in the logistic regression analysis. The logistic regression model included other important variables, including age, baseline comorbidities, and index hospitalization characteristics shown in Table 1. R's MatchIt package was used for propensity matching.¹⁴ To account for potential confounding and selection bias, a propensity score–matching model was developed using logistic regression to derive 2 matched groups for comparative outcomes analysis of patients readmitted with HF compared with patients who were not readmitted with HF. A nearest-neighbor 1:1 variable ratio, parallel, balanced propensity-matching model without replacement was made using caliper of width equal to 0.2 of the SDs of the logit of the propensity score. Age, sex, and baseline comorbidities related to the readmission hospitalizations were included in propensity matching. Outcomes during rehospitalization for HF and non-HF 30-day readmissions were reported. The variables with missing data were categorized as “others/missing” before matching. Index hospitalization characteristics or variables directly related to the outcome for the readmissions were not included. A second multivariable logistic regression model adjusted for age, sex, and baseline comorbidities was also developed that used nonweighted data from the year 2018 to assess readmission outcomes for high and medium discharge volume hospitals compared with low-volume hospitals as a reference group. For missing values in the non-weighted data, listwise deletion was used, and missing values were not included in the logistic regression analysis.

For weighted analysis from quarter 4 of 2015 to 2018, complete data were available for all variables except for primary expected payer (0.1%), disposition (<0.1%), elective index admission (0.4%), elective readmissions (<0.1%), and median household income (1.3%). In the unweighted sample of 2018 data, all variables had complete data except for primary expected payer (0.1%), elective index admission (<0.1%), elective readmission (0.1%), and median household income (1.2%). All missing values are reported in Table 1 and Tables S1, S2, and S3 and have been recoded as “others/missing.”

For all analyses, a 2-tailed *P* value of 0.05 was considered statistically significant. Analyses were performed using SPSS version 27 and R software for statistical computing version 4.3. Discharge weights provided by the NRD were used for all weighted analyses except for annual hospital discharge volume analysis for which only unweighted data from the year 2018 were used.

Table 1. Baseline Characteristics and Predictors of 30-Day Readmission for HF After Transcatheter Aortic Valve Replacement

	Univariate analysis, 30-day HF readmission		Unadjusted odds ratio (95% CI)	P value	Adjusted multivariable analysis	
	Without readmission, n=148329; median (IQR) or n (%)	With 30-day HF readmission, n=5962; median (IQR) or n (%)			Adjusted odds ratio (95% CI)	P value
Age, y	81 (75–86)	83 (76–87)				
Age categories, y						
≤64	7512 (5.1)	239 (4.0)	Reference		Reference	0.16
65–74	26974 (18.2)	1020 (17.1)	1.19 (1.03–1.37)	0.02	1.12 (0.96–1.31)	0.52
75–84	62842 (42.4)	2321 (38.9)	1.16 (1.02–1.33)	0.03	0.95 (0.81–1.11)	0.99
≥85	51001 (34.4)	2382 (40.0)	1.47 (1.28–1.68)	<0.01	1.00 (0.85–1.18)	0.16
Charlson Comorbidity Index	7 (6–8)	8 (7–9)				
Charlson Comorbidity Index score >8	57915 (39.0)	3415 (57.3)	2.09 (1.99–2.21)	<0.01	1.29 (1.20–1.39)	<0.01
Elective index admission	120366 (81.4)	4037 (68.0)	0.49 (0.46–0.51)	<0.01	0.92 (0.86–0.98)	0.01
Female sex	67678 (45.6)	2766 (46.4)	1.03 (0.98–1.09)	0.25
Primary payer						
Medicare	134856 (90.9)	5527 (92.7)	Reference		Reference	
Medicaid	1588 (1.1)	52 (0.9)	0.79 (0.61–1.05)	0.10	0.82 (0.61–1.10)	0.19
Private insurance	8613 (5.8)	274 (4.6)	0.78 (0.69–0.88)	<0.01	0.99 (0.86–1.13)	0.82
Self-pay	534 (0.4)	22 (0.4)	0.99 (0.64–1.52)	0.95	0.89 (0.57–1.39)	0.60
Other [†]	2561 (1.7)	79 (1.3)	0.76 (0.61–0.96)	0.02	0.86 (0.68–1.08)	0.18
Others/missing [†]	177 (0.1)	9 (0.1)
Median quartile of income						
0–25th percentile	30144 (20.3)	1247 (20.9)	Reference			
25–50th percentile	40254 (27.1)	1574 (26.4)	0.95 (0.88–1.02)	0.14
50–75th percentile	40177 (27.1)	1645 (27.6)	0.99 (0.92–1.07)	0.79
75–100th percentile	35869 (24.2)	1413 (23.7)	0.95 (0.88–1.03)	0.22
Others/missing [†]	1885 (1.3)	84 (1.4)
Hospital size						
Small	6699 (4.5)	243 (4.1)	Reference			
Medium	30564 (20.6)	1257 (21.1)	1.13 (0.98–1.30)	0.08
Large	111066 (74.9)	4462 (74.8)	1.11 (0.97–1.26)	0.13
Hospital teaching						
Metropolitan nonteaching	15961 (10.8)	607 (10.2)	Reference			

(Continued)

Table 1. Continued

	Univariate analysis, 30-day HF readmission				Adjusted multivariable analysis		
	Without readmission, n=148 329; median (IQR) or n (%)	With 30-day HF readmission, n=5962; median (IQR) or n (%)	Unadjusted odds ratio (95% CI)		Adjusted odds ratio (95% CI)	P value	
Metropolitan teaching	130 993 (88.3)	5290 (88.7)	1.06 (0.98–1.16)		
Nonmetropolitan hospital	1375 (0.9)	65 (1.1)	1.24 (0.96–1.61)		
Anemias	6034 (4.1)	548 (9.2)	2.39 (2.18–2.62)		1.70 (1.55–1.88)	<0.01	
Alcohol use	94 (0.1)	<11 <0.1*	0.27 (0.04–1.91)		
Hypertension	132 235 (89.1)	5391 (90.4)	1.15 (1.05–1.26)		0.99 (0.90–1.09)	0.83	
Diabetes	25 956 (17.5)	929 (15.6)	0.87 (0.81–0.94)		0.98 (0.91–1.06)	0.64	
Coronary artery disease	104 023 (70.1)	4141 (69.5)	0.97 (0.92–1.03)		
Cerebrovascular disease	16 403 (11.1)	543 (9.1)	0.81 (0.74–0.88)		0.69 (0.63–0.76)	<0.01	
Chronic obstructive pulmonary disease	42 845 (28.9)	2162 (36.3)	1.40 (1.33–1.48)		1.23 (1.16–1.31)	<0.01	
Pulmonary circulation disorder	28 272 (19.1)	1404 (23.6)	1.31 (1.23–1.39)		0.93 (0.88–1.00)	0.05	
Obesity	28 406 (19.2)	945 (15.9)	0.81 (0.74–0.85)		0.76 (0.70–0.82)	<0.01	
Prior MI	18 723 (12.6)	803 (13.5)	1.08 (0.99–1.16)		
Prior PCI	29 895 (20.2)	1156 (19.4)	0.95 (0.89–1.02)		
Prior CABG	27 210 (18.3)	1123 (18.8)	1.03 (0.97–1.10)		
Preexisting pacemaker	14 949 (10.1)	1265 (21.2)	2.40 (2.25–2.56)		2.18 (2.04–2.33)	<0.01	
Pacemaker implanted during index hospitalization	14 747 (9.9)	831 (13.9)	1.47 (1.36–1.58)		1.08 (0.97–1.20)	0.15	
Complete heart block during index hospitalization	13 648 (9.2)	785 (13.2)	1.51 (1.39–1.62)		1.20 (1.08–1.33)	<0.01	
Prior ICD	3854 (2.6)	13 (0.2)	1.96 (1.74–2.21)		1.77 (1.55–2.01)	<0.01	
Weight loss	4576 (3.1)	518 (8.7)	2.99 (2.72–3.29)		1.71 (1.54–1.89)	<0.01	
Peripheral vascular disease	31 157 (21.0)	935 (15.7)	0.71 (0.65–0.75)		0.60 (0.55–0.64)	<0.01	
Atrial fibrillation	59 545 (40.1)	3562 (59.7)	2.21 (2.10–2.33)		1.63 (1.54–1.73)	<0.01	
Liver disease	4480 (3.0)	259 (4.3)	1.46 (1.28–1.66)		1.25 (1.09–1.43)	<0.01	
Chronic kidney disease	32 721 (22.1)	2140 (35.9)	1.98 (1.87–2.09)		1.47 (1.37–1.57)	<0.01	
End-stage renal disease	5826 (3.9)	402 (6.7)	1.77 (1.59–1.96)		1.56 (1.39–1.76)	<0.01	
Paravalvular regurgitation	613 (0.4)	57 (1.0)	2.33 (1.77–3.06)		2.07 (1.56–2.75)	<0.01	
Mitral stenosis	1327 (0.9)	84 (1.4)	1.58 (1.27–1.98)		1.32 (1.04–1.67)	0.02	

Table 1. Continued

	Univariate analysis, 30-day HF readmission				Unadjusted odds ratio (95% CI)	P value	Adjusted multivariable analysis		P value
	Without readmission, n=148 329; median (IQR) or n (%)	With 30-day HF readmission, n=5962; median (IQR) or n (%)					Adjusted odds ratio (95% CI)		
Mitral regurgitation	10 476 (7.1)	522 (8.8)			1.26 (1.15–1.38)	<0.01	1.04 (0.95–1.15)		0.38
HF with reduced EF	18 265 (12.3)	1550 (26.0)			2.50 (2.36–2.66)	<0.01	3.24 (3.00–3.51)		<0.01
HF with preserved EF	64 057 (43.2)	3383 (56.7)			1.73 (1.64–1.82)	<0.01	2.69 (2.52–2.87)		<0.01
Length of stay >4 d during index hospitalization	51 076 (34.4)	3531 (59.2)			2.77 (2.62–2.92)	<0.01	1.76 (1.65–1.88)		<0.01
Nonhome/facility discharge during index hospitalization	54 641 (36.8)	112 (3363)			2.22 (2.11–2.34)	<0.01	1.40 (1.31–1.48)		<0.01

Descriptive statistics and regression model are based on weighted data. CABG indicates coronary artery bypass graft surgery; EF, ejection fraction; HF, heart failure; ICD, implantable cardioverter defibrillator; IQR, interquartile range; MI, myocardial infarction; and PCI, percutaneous coronary intervention.

*Observations <11 are not reported per Healthcare Cost and Utilization Project guidelines.

†“Other” variable includes Workers’ Compensation and other government programs.

‡The missing values were recoded as “others/missing.”

RESULTS

Baseline Characteristics of the Study Population

A total of 167345 weighted hospitalizations for TAVR were identified. Of the included patients, 148329 did not get readmitted. The all-cause readmission rate within 30 days of discharge was 11.4% (19016). The incidence of HF readmissions was 3.6% (5962), accounting for 31.4% of all-cause 30-day readmissions. Non-HF readmissions were 7.8% (13054). HF readmission occurred at a median of 9 days (IQR, 4–17 days) after discharge, whereas non-HF readmission occurred at a median of 10 days (IQR, 4–19 days; $P<0.01$). Patients readmitted with HF had a higher comorbidity burden with a Charlson comorbidity median score of 8 (IQR, 7–9) versus 7 (IQR, 6–8) among patients with other causes of readmission ($P<0.01$). The baseline characteristics are summarized in Table 1 and Table S2.

Predictors of 30-Day HF Readmissions

A total of 148329 index hospitalizations (after excluding index cases that were readmitted for non-HF causes, $n=13054$) were compared with 5962 30-day HF readmissions. Independent predictors of 30-day HF readmission after TAVR included the following: Charlson comorbidity score >8 (odds ratio [OR], 1.29; 95% CI, 1.20–1.39), LOS >4 days on index hospitalization (OR, 1.76; 95% CI, 1.65–1.88), nonhome/facility discharge on index admission (OR, 1.40; 95% CI, 1.31–1.48), diagnosis of anemia (OR, 1.70; 95% CI, 1.55–1.88), chronic obstructive pulmonary disease (OR, 1.23; 95% CI, 1.16–1.31), diagnosis of atrial fibrillation (OR, 1.63; 95% CI, 1.54–1.73), paravalvular regurgitation (OR, 2.07; 95% CI, 1.56–2.75), preexisting permanent pacemaker (PPM) on index hospitalization (OR, 1.08; 95% CI, 0.97–1.20), complete heart block during index hospitalization (OR, 1.20; 95% CI, 1.08–1.33), chronic kidney disease (CKD; OR, 1.47; 95% CI, 1.37–1.57), and end-stage renal disease (ESRD; OR, 1.56; 95% CI, 1.39–1.76). In contrast, elective index admission (OR, 0.92; 95% CI, 0.86–0.98) was associated with a lower likelihood of readmission within a month after discharge (Table 1, Figure 2).

Outcomes of HF Readmissions Compared With Readmissions Without HF

A total of 5962 HF readmissions were compared with non-HF readmissions (12864) after excluding patients with missing data on mode of readmission ($n=190$). The detailed baseline characteristics of HF versus non-HF readmissions before and after propensity matching are given in Table S3. The covariate balance before and




Figure 2. Independent predictors of 30-day readmissions for HF.

Estimates are based on weighted data. CHB indicates complete heart block; EF, ejection fraction; ICD, implantable cardioverter defibrillator; and PPM, permanent pacemaker.

after propensity matching are shown in Figure S1. Non-propensity-matched and propensity-matched outcomes mirrored each other with minimal differences. HF readmissions were associated with higher mortality when compared with non-HF readmissions (4.9% versus 3.3%; $P < 0.01$). Similarly, more patients with HF readmissions were discharged to facilities than non-HF readmission patients (68.3% versus 56.8%; $P < 0.01$). Moreover, cardiogenic shock (3.2% versus 1.0%; $P < 0.01$) and acute kidney injury (35.1% versus 20.8%; $P < 0.01$) were higher on readmission with HF (Table 2).

Temporal Trends for All-Cause and HF Readmissions

Temporal trends showed that all-cause readmissions decreased significantly from 12.3% to 11% ($P_{\text{trend}} = 0.03$). However, HF readmissions showed a nonsignificant downward trend from 4.1% in 2015 to 3.4% in 2018 ($P_{\text{trend}} = 0.06$; Figure 3). Similarly, all-cause readmission mortality and HF readmission mortality showed a nonsignificant downward trend from 2015 to 2018 ([5.9% to 3.6% [$P_{\text{trend}} = 0.2$] and 8.9% to 5%

Table 2. Hospital Outcomes and Resource Use Associated With 30-Day Readmission After Transcatheter Aortic Valve Replacement

	Crude analysis		1:1 Propensity matching			
	Without HF readmission, n=12864	With HF readmission, n=5962	P value	Without HF readmission, n=5962	With HF readmission, n=5962	P value
Died during hospitalization	420 (3.3)	292 (4.9)	<0.01	230 (3.9)	292 (4.9)	0.01
Discharge disposition			<0.01			<0.01
Routine home discharge	5556 (43.2)	1887 (31.6)		2365 (39.7)	1887 (31.6)	
SNF/facility discharge	7304 (56.8)	4076 (68.3)		3595 (60.3)	4076 (68.3)	
Vascular complications	680 (5.3)	231 (3.9)	<0.01	296 (5.0)	231 (3.9)	<0.01
Cardiogenic shock	125 (1.0)	189 (3.2)	<0.01	75 (1.3)	189 (3.2)	<0.01
Acute kidney injury	2680 (20.8)	2092 (35.1)	<0.01	1599 (26.8)	2092 (35.1)	<0.01
Permanent pacemaker	1481 (11.5)	374 (6.3)	<0.01	607 (10.2)	374 (6.3)	<0.01
Urinary tract infection	1609 (12.5)	685 (11.5)	0.31	836 (14.0)	685 (11.5)	<0.01
Pneumonia	887 (6.9)	732 (12.3)	<0.01	463 (7.8)	732 (12.3)	<0.01
Gastrointestinal bleed	839 (6.5)	236 (4.0)	<0.01	463 (7.8)	236 (4.0)	<0.01
Ischemic stroke	701 (5.4)	119 (2.0)	<0.01	224 (3.7)	119 (2.0)	<0.01
Hemorrhagic stroke	114 (0.9)	48 (0.8)	0.04	25 (0.4)	48 (0.8)	0.01
Resource use						
LOS (days)	3 (5–6)	5 (3–8)	<0.01	4 (2–6)	5 (3–8)	<0.01
Hospitalization cost (USD)	\$11 351 (\$6403–\$20 440)	\$12 928 (\$7087–\$24 780)	<0.01	\$11 935 (\$6540–\$21 303)	\$12 673 (\$6768–\$25 172)	<0.01

Data are provided as number (percentage) or median (interquartile range). HF indicates heart failure; LOS, length of stay; and SNF, skilled nursing facility.

[$P_{\text{trend}}=0.3$], respectively)). Across all years, HF readmission mortality was significantly higher than all-cause readmission mortality (Figure 3A and 3B).

Association of Hospital TAVR Discharge Volume With All-Cause and HF Readmissions

In terms of hospital TAVR volumes, 3371 cases of TAVR were performed in low-volume, 9653 cases in medium-volume, and 21716 cases in high-volume hospitals during 2018, respectively. The detailed baseline characteristics are given in Table S4. Adjusted all-cause readmissions were similar in high-volume centers (OR, 0.97; 95% CI, 0.86–1.10) compared with low-volume centers. Similarly, HF readmission rates were comparable across low-, medium-, and high-volume centers (Table S5).

Resource Use for HF Readmissions Compared With Readmissions Without HF

Each 30-day HF readmission was associated with a \$12 928 greater increase in the cost of care than each non-HF readmission ($P\leq 0.01$). Similarly, LOS on readmission was significantly higher for HF readmission compared with non-HF readmissions (5 days versus 3 days; $P<0.01$; Table 2, Figure S2).

DISCUSSION

We report 6 principal findings from our analysis of TAVR hospitalizations using a large, contemporary, nationwide readmission data set. First, 3.6% of 30-day readmissions are attributed to HF and account for 31.4% of all-cause readmissions. Second, all-cause readmission rates after TAVR showed a significant downtrend, whereas HF rehospitalizations remained steady. Third, Charlson Comorbidity Index >8 , LOS >4 days during the index hospitalization, anemia, chronic obstructive pulmonary disease, atrial fibrillation, paravalvular regurgitation, HF with reduced ejection fraction, HF with preserved ejection fraction, preexisting PPM, complete heart block during the index hospitalization, CKD, and ESRD were independent predictors of 30-day HF readmission after TAVR. Fourth, patients with HF readmissions have significantly higher readmission mortality compared with non-HF readmissions. Fifth, there was no difference between HF readmission rates, all-cause mortality, or HF readmission mortality between high-, medium- and low-volume TAVR centers. Sixth, post-TAVR HF readmissions are associated with significantly higher cost and duration of hospital stay during readmissions than non-HF readmissions.



Figure 3. Temporal trends in HF and all-cause readmissions after transcatheter aortic valve replacement. Estimates are based on weighted data. HF indicates heart failure.

Readmission Rates and Temporal Trends

Outcomes after TAVR are increasingly in focus as the indication expanded from high-risk and intermediate-risk cohorts to low-risk cohorts. Over time, the LOS has declined, and conscious sedation is increasingly used in current practice.⁵ Previous studies have reported a wide range for all-cause 30-day readmission rates from 9% to 19%.^{5,15–18} Kolte et al analyzed data from the 2013 US NRD and showed an all-cause readmission rate of 17.9%, with 38.2% of readmissions attributed to cardiovascular causes. In their study, HF was the most common cause of all-cause readmission in 22.5% of the cases.⁶ Our contemporary analysis from the most recent NRD data shows a much lower all-cause readmission rate of 11.4% and an HF rehospitalization rate of 3.6% at 30 days. Our study complements the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) Transcatheter Valve Therapies (TVT) Registry study, which showed that all-cause readmission rates have decreased over time, with our study providing the most recent data.⁵ However, it is important to note that a similar significant downtrend has not been noted with HF readmissions. HF readmissions are the most common causes of rehospitalizations in patients with TAVR, with reported rates between 20% and 40% of all-cause readmissions (Kolte et al, 22.5%⁶; Nombela-Franco et al, 30.4%¹⁵). Moreover, Tripathi and colleagues reported a readmission rate of 77% for all cardiovascular causes, including HF at 90 days after discharge from their analysis of NRD data from 2016 to 2017.¹⁶ The variation in reported HF readmissions in the aforementioned studies is attributed to the heterogeneity in the time frame (30 days versus 90 days) and the type of study (single center versus administrative data sets). The HF rehospitalization rate of 3.6% at 30 days is consistent with prior studies using administrative claim codes.¹⁷

Predictors of Readmission

We identified important independent predictors of 30-day rehospitalizations with HF. We reinforce the finding of an earlier study that postprocedure paravalvular leak leads to a 2-fold higher risk of readmission with HF.¹⁸ Multiple prior studies have reported anemia as a significant predictor of HF rehospitalizations. Anemia can lead to a high output state and precipitate HF exacerbation. Moreover, blood transfusions to treat anemia can lead to volume overload and precipitation of HF, leading to early readmissions.⁷ Similarly, pulmonary hypertension is also a well-known predictor of HF readmission, which has been previously identified.^{7,19,20} In our univariate analysis, a significantly higher percentage of patients with HF readmissions had pulmonary hypertension. Pulmonary hypertension attributed to postcapillary or combined pre- and postcapillary

causes is associated with poor outcomes and is also a risk factor for mortality after TAVR.²¹ Hence, it is suggested that patients undergo an evaluation to identify precapillary, postcapillary, or combined capillary pulmonary hypertension and risk stratify these patients.⁷ Expectedly, chronic HF was associated with increased 30-day readmissions, with HF with reduced ejection fraction being a stronger predictor than HF with preserved ejection fraction. Atrial fibrillation is a disease of the elderly and common comorbidity in patients with aortic stenosis and is an independent predictor of HF readmission. Furthermore, preexisting PPM on index hospitalization was an independent predictor of readmission along with complete heart block. However, although significant on univariate analysis, new PPM implantation during the first hospitalization was not predictive of HF readmission. Previous studies reported a nonsignificant association between preexisting PPM and all-cause readmissions after TAVR at 30 days but a significant association at 90 days.^{6,16} Finally, increased LOS >4 days during the index hospitalization increases the likelihood of 30-day readmission, whereas Charlson Comorbidity Index >8 predicts a 1.4 times higher risk of 30-day rehospitalization after TAVR. Our study supports the findings of the prior studies, which reported increased LOS during index hospitalization and higher comorbidity burden as predictors of readmissions.^{6,16}

Frailty is prevalent in the TAVR population²² and is a risk factor for death and disability after TAVR. Weight loss is an indicator of frailty in the elderly population.²³ We report weight loss to be a significant predictor of readmission. Interventions to address sarcopenia should focus on diet and exercise with cardiac rehabilitation being 1 such intervention after TAVR.²⁴

The CKD-ESRD subgroup is associated with poor outcomes both in hospital and at 1 year. We report an increased risk for HF-related readmissions in this subgroup. CKD and ESRD are well-known risk factors for readmission in the HF population.²⁵ This could be related to a cardiorenal syndrome where worsening kidney function can precipitate HF. TAVR has a beneficial effect on improving kidney function in a majority of patients, but a quarter of patients experience deteriorating kidney function.²⁶ It is likely that this subgroup could be at higher risk for readmissions from the cardiorenal syndrome and more so in those with worsening CKD or acute kidney injury after TAVR.²⁷

Readmission Mortality

The significantly increased mortality rate in those with 30-day HF readmission after TAVR is concerning. This finding warrants further exploration. Prior studies suggest that cardiovascular mortality accounts for ≈72% of deaths for HF readmission compared with 19% for

non-HF readmissions.¹⁵ Our study complements the findings of a prior study by Durand et al⁷ that reported a worse prognosis with single and multiple HF readmissions at 30-day follow-up.

Paravalvular leak and worsening or residual valve lesions are known predictors of mortality after TAVR. The presence of a moderate or severe paravalvular leak is a predictor of both short-term and long-term mortality in addition to HF readmissions as discussed previously.²⁸ On univariate analysis, valve disease especially involving the mitral valve was significantly higher in the HF readmission group. However, the adjusted analysis did not reveal a significant association for mitral regurgitation. Persistent mitral regurgitation after TAVR is associated with poor functional class and mortality.^{29,30} Mitral stenosis is also associated with an increased risk of mortality and HF rehospitalization at 1 year.³¹ Similarly, worsening tricuspid regurgitation is shown to be a predictor of all-cause and cardiovascular mortality after TAVR.³² These residual valve lesions may predict 30-day HF readmission mortality and readmissions when evaluated for a longer time frame. Cardiac amyloidosis is increasingly recognized as a coexistent pathology in the TAVR population and is seen in 1 in 8 patients referred for TAVR. Patients with amyloidosis may be at risk for HF readmission and higher mortality because of the continued remodeling despite decreasing the afterload.³³ Our study could not evaluate the role of amyloidosis because of the very low numbers, which could be attributed to underdiagnosis.

Hospital Volume and Readmission

There has been a great interest in studying hospital TAVR discharge volumes and outcomes.^{9,10} Studies to date suggest an inverse relationship between hospital volume and mortality, with higher volume centers having less mortality. Our study did not find a significant mortality difference between high- and medium-volume hospitals compared with low-volume hospitals. A 2014 NRD analysis by Khera et al reported an inverse relationship between hospital discharge volume and all-cause readmission rates after TAVR (25% lower admission in high-volume centers compared with low-volume centers).¹⁰ Novel to our study is the lack of association between hospital TAVR discharge volume not only for all-cause but also HF readmissions. We hypothesize that the patient-level characteristics discussed previously play a significant role in HF readmissions rather than hospital-level factors and should be the focus of future interventions.⁷

Cost and LOS

HF hospitalizations are a significant burden on the health care system given that each readmission leads to ~\$13 000 excess cost per readmission. Our reported

cost estimates adjusted for inflation agree with earlier reported estimates.^{6,16} It is perhaps attributed to the increased incidence of cardiogenic shock requiring intensive care unit admissions, higher complications such as acute kidney injury, and the increased use of mechanical circulatory devices such as percutaneous left ventricular assist device and Impella that increase the duration of hospital stays attributed to HF rehospitalization, which led to an increased cost of hospitalizations.^{34,35} Early follow-up (<1 week) is a key intervention associated with reduced readmission after HF hospitalization.³⁶ A similar intervention can be considered part of the transition of care planning after hospital discharge after TAVR in those at high risk for HF readmission. Our study data may help identify a specific subset of patients—those with a prolonged index hospital stay, higher Charlson Comorbidity Index, anemia, chronic obstructive pulmonary disease, preexisting PPM, atrial fibrillation, valvular disease, kidney disease, and chronic HF—who will benefit from interventions to prevent readmission, including early discharge follow-up. We suggest further research to develop postdischarge interventions for this cohort to help mitigate the risk of readmissions and consequently reduce the cost.

LIMITATIONS

Previous studies have shown that aortic valve gradient, postprocedure left ventricular ejection fraction, and the presence of amyloidosis are significant predictors of HF readmission.³⁷ We could not study these factors because of the nonavailability or undercoding of *ICD-10-CM* codes for these conditions.⁷ Our study looked at unweighted data for a national analysis of the association between TAVR hospital volume and readmission rates. However, the NRD is not designed to study hospital-level outcome data. The NRD cannot capture deaths that occur outside of the hospital.³⁸ Studies are needed to assess the impact of hospital TAVR volume on readmission outcomes. Moreover, data on medication use and blood chemistry are lacking; hence, we could not factor in the role of medication noncompliance.⁸ TAVR-based outcomes such as patient prosthesis mismatch and valve dysfunction/thrombosis data could not be evaluated because of lack of echocardiographic data. Valve-related readmissions contribute to <10% of all readmissions, according to a recent study.⁵ The NRD is an administrative claim-based database that uses *ICD-10-CM* codes for diagnosis. Although procedural codes are less prone to error, coding errors and variability cannot be excluded entirely. The NRD collects data on in-patient discharges, and each admission is registered as an independent event. Furthermore, emergency room visits

after TAVR are not captured by the NRD and hence are not included in our analysis. Similar to any observational, retrospective study, association does not imply causation, and conclusions are hypothesis generating and should be drawn cautiously.

CONCLUSIONS

The incidence of 30-day readmission for HF after TAVR was 3.6%, which accounts for 31.4% of all-cause readmissions. Although 30-day all-cause readmissions after TAVR have decreased in recent years, HF readmissions have not shown a significant downward trend. Increased hospital TAVR volume is not associated with reduced HF readmissions. Patient characteristics associated with 30-day HF readmissions include LOS >4 days during the index hospitalization, anemia, chronic obstructive pulmonary disease, paravalvular leak, atrial fibrillation, HF with reduced ejection fraction, HF with preserved ejection fraction, preexisting pacemaker, complete heart block on index hospitalization, CKD, and ESRD. Given the retrospective nature of the study, our study findings should be considered hypothesis generating. Further prospective studies are needed to identify strategies to decrease the burden of HF readmissions and readmission mortality after TAVR.

ARTICLE INFORMATION

Received November 30, 2021; accepted June 29, 2022.

Affiliations

Department of Medicine, Rochester General Hospital, Rochester, NY (S.Z., D.R., A.E.); Department of Internal Medicine, Allegheny Health Network, Pittsburgh, PA (M.T.D.); Division of Cardiology, West Virginia University Heart & Vascular Institute, Morgantown, WV (M.Z.K., M.U.K., S.B.); Department of Cardiovascular Medicine, Jefferson University Hospitals, Philadelphia, PA (W.U.); Division of Cardiovascular Medicine, Cleveland Clinic Florida, Weston, FL (A.S.); Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE (A.M.G.); Kaweah Health Medical Center, Visalia, CA (A.S.); and Division of Cardiovascular Medicine, University of California Los Angeles, Los Angeles, CA (G.F.).

Sources of Funding

None.

Disclosures

None.

Supplemental Material

Tables S1-S5
Figures S1-S2

REFERENCES

- Cribier A, Eltchaninoff H, Tron C. First human transcatheter implantation of an aortic valve prosthesis in a case of severe calcific aortic stenosis. *Ann Cardiol Angeiol (Paris)*. 2003;52:173–175. doi: 10.1016/s0003-3928(03)00062-3
- Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med*. 2011;364:2187–2198. doi: 10.1056/NEJMoa1103510
- Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. *N Engl J Med*. 2016;374:1609–1620. doi: 10.1056/NEJMoa1514616
- Russo MJ, JM MC, Thourani VH, Guerrero M, Genereux P, Nguyen T, Hong KN, Kodali S, Leon MB. Case volume and outcomes after TAVR with balloon-expandable prostheses. *J Am Coll Cardiol*. 2019;73:427–440. doi: 10.1016/j.jacc.2018.11.031
- Sanchez CE, Hermiller JBJ, Pinto DS, Chetcuti SJ, Arshi A, Forrest JK, Huang J, Yakubov SJ. Predictors and risk calculator of early unplanned hospital readmission following contemporary self-expanding transcatheter aortic valve replacement from the STS/ACC TVT registry. *Cardiovasc Revasc Med*. 2020;21:263–270. doi: 10.1016/j.carrev.2019.05.032
- Kolte D, Khera S, Sardar MR, Gheewala N, Gupta T, Chatterjee S, Goldsweig A, Aronow WS, Fonarow GC, Bhatt DL, et al. Thirty-day readmissions after transcatheter aortic valve replacement in the United States: Insights from the Nationwide readmissions database, Circulation. *Cardiovasc Interv Ther*. 2017;10. doi: 10.1161/CIRCINTERVENTIONS.116.004472
- Durand E, Doutriaux M, Bettinger N, Tron C, Fauvel C, Bauer F, Dachet J-N, Bouhram N, Litzler P-Y, Cribier A, et al. Incidence, prognostic impact, and predictive factors of readmission for heart failure after transcatheter aortic valve replacement. *JACC Cardiovasc Interv*. 2017;10:2426–2436. doi: 10.1016/j.jcin.2017.09.010
- Auffret V, Bakhti A, Leurent G, Bedossa M, Tomasi J, Belhaj Soulam R, Verhoye J-P, Donal E, Galli E, Loirat A, Sharobeem S, Sost G, le Guellec M, Boulmier D, le Breton H Determinants and impact of heart failure readmission following transcatheter aortic valve replacement. *Circ Cardiovasc Interv* 2020;13:e008959. DOI: 10.1161/CIRCINTERVENTIONS.120.008959
- Vemulapalli S, Carroll JD, Mack MJ, Li Z, Dai D, Kosinski AS, Kumbhani DJ, Ruiz CE, Thourani VH, Hanzel G, et al. Procedural volume and outcomes for transcatheter aortic-valve replacement. *N Engl J Med*. 2019;380:2541–2550. doi: 10.1056/NEJMsa1901109
- Khera S, Kolte D, Gupta T, Goldsweig A, Velagapudi P, Kalra A, Tang GHL, Aronow WS, Fonarow GC, Bhatt DL, et al. Association between hospital volume and 30-day readmissions following transcatheter aortic valve replacement. *JAMA Cardiol*. 2017;2:732–741. doi: 10.1001/jamacardio.2017.1630
- Overview of the Nationwide Readmission Database (NRD). Agency for Healthcare Research and Quality, Rockville, MD. 2020.
- Cost-to-Charge Ratio Files. Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality, Rockville, MD. 2020.
- Consumer Price Index: U.S. Bureau of Labor Statistics; 2020 [updated Jun. 10, 2020. Available from <https://www.bls.gov/cpi/>]
- Ho D, Imai K, King G, Stuart EA. MatchIt: Nonparametric preprocessing for parametric causal inference. *J Stat Softw* 2011;42(SE-Articles):1–28. DOI: 10.1186/s40246-018-0156-4
- Nombela-Franco L, del Trigo M, Morrison-Polo G, Veiga G, Jimenez-Quevedo P, Abdul-Jawad Altisent O, Campelo-Parada F, Biagioni C, Puri R, DeLarochelière R, et al. Incidence, causes, and predictors of early (≤ 30 days) and late unplanned hospital readmissions after transcatheter aortic valve replacement. *JACC Cardiovasc Interv*. 2015;8:1748–1757. doi: 10.1016/j.jcin.2015.07.022
- Tripathi B, Nerusu LA, Sawant AC, Atti L, Sharma P, Pershad A. Transcatheter aortic valve implantation readmissions in the current era (from the National Readmission Database). *Am J Cardiol*. 2020;130:115–122. doi: 10.1016/j.amjcard.2020.06.020
- Holmes DRJ, Brennan JM, Rumsfeld JS, Dai D, O'Brien SM, Vemulapalli S, Edwards FH, Carroll J, Shahian D, Grover F, et al. Clinical outcomes at 1 year following transcatheter aortic valve replacement. *JAMA*. 2015;313:1019–1028. doi: 10.1001/jama.2015.1474
- Pibarot P, Hahn RT, Weissman NJ, Arsenault M, Beaudoin J, Bernier M, Dahou A, Khaliq OK, Asch FM, Toubal O, et al. Association of Paravalvular Regurgitation with 1-year outcomes after transcatheter aortic valve replacement with the SAPIEN 3 valve. *JAMA Cardiol*. 2017;2:1208–1216. doi: 10.1001/jamacardio.2017.3425
- Luçon A, Oger E, Bedossa M, Boulmier D, Verhoye JP, Eltchaninoff H, lung B, Leguerrier A, Laskar M, Leprince P, et al. Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis

- undergoing transcatheter aortic valve implantation: study from the France 2 registry. *Circ Cardiovasc Interv.* 2014;7:240–247. doi: [10.1161/CIRCINTERVENTIONS.113.000482](#)
20. O'Sullivan CJ, Wenaweser P, Ceylan O, Rat-Wirtzler J, Stortecky S, Heg D, Spitzer E, Zanchin T, Praz F, Tüller D, et al. Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: Insights from the new proposed pulmonary hypertension Classificat. *Circ Cardiovasc Interv.* 2015;8:e002358. doi: [10.1161/CIRCINTERVENTIONS.114.002358](#)
 21. Lachmann M, Rippen E, Schuster T, Xhepa E, von Scheidt M, Pellegrini C, Trenkwalder T, Rheude T, Stundl A, Thalmann R, et al. Subphenotyping of patients with aortic stenosis by unsupervised agglomerative clustering of echocardiographic and hemodynamic data. *JACC Cardiovasc Interv.* 2021;14:2127–2140. doi: [10.1016/j.jcin.2021.08.034](#)
 22. Afilalo J, Lauck S, Kim DH, Lefèvre T, Piazza N, Lachapelle K, Martucci G, Lamy A, Labinaz M, Peterson MD, et al. Frailty in older adults undergoing aortic valve replacement: The FRAILTY-AVR study. *J Am Coll Cardiol.* 2017;70:689–700. doi: [10.1016/j.jacc.2017.06.024](#)
 23. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, et al. Frailty in older adults: Evidence for a phenotype. *The journals of gerontology. Series A, Biological sciences and medical sciences.* 2001;56:M146–M156. doi: [10.1093/gerona/56.3.m146](#)
 24. Epstein E, Rosander A, Pazargadi A, Taub P. Cardiac rehab for functional improvement. *Curr Heart Fail Rep.* 2020;17:161–170. doi: [10.1007/s11897-020-00462-2](#)
 25. Fudim M, O'Connor CM, Dunning A, Ambrosy AP, Armstrong PW, Coles A, Ezekowitz JA, Greene SJ, Metra M, Starling RC, et al. Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: Insights from ASCEND-HF. *Eur J Heart Fail.* 2018;20:304–314. doi: [10.1002/ehf.1020](#)
 26. Witberg G, Steinmetz T, Landes U, Pistiner Hanit R, Green H, Goldman S, Vaknin-Assa H, Codner P, Perl L, Rozen-Zvi B, et al. Change in kidney function and 2-year mortality after transcatheter aortic valve replacement. *JAMA Netw Open.* 2021;4:e213296. doi: [10.1001/jamanetworkopen.2021.3296](#)
 27. Vavilis G, Evans M, Jernberg T, Rück A, Szummer K. Risk factors for worsening renal function and their association with long-term mortality following transcatheter aortic valve implantation: Data from the SWEDEHEART registry. *Open Heart.* 2017;4:e000554. doi: [10.1136/openhrt-2016-000554](#)
 28. Lerakis S, Hayek SS, Douglas PS. Paravalvular aortic leak after transcatheter aortic valve replacement. *Circulation.* 2013;127:397–407. doi: [10.1016/j.jacc.2019.06.076](#)
 29. Cortés C, Amat-Santos IJ, Nombela-Franco L, Muñoz-García AJ, Gutiérrez-Ibanes E, de La Torre Hernández JM, Córdoba-Soriano JG, Jiménez-Quevedo P, Hernández-García JM, González-Mansilla A, et al. Mitral regurgitation after transcatheter aortic valve replacement: Prognosis, imaging predictors, and potential management. *JACC Cardiovasc Interv.* 2016;9:1603–1614. doi: [10.1016/j.jcin.2016.05.025](#)
 30. Witberg G, Codner P, Landes U, Schwartzberg S, Barbanti M, Valvo R, De Backer O, Ooms JF, Islas F, Marroquin L, et al. Effect of transcatheter aortic valve replacement on concomitant mitral regurgitation and its impact on mortality. *J Am Coll Cardiol Interv.* 2021;14:1181–1192. DOI: [10.1016/j.jcin.2021.02.030](#)
 31. Joseph L, Bashir M, Xiang Q, Yerokun BA, Matsouaka RA, Vemulapalli S, Kapadia S, Cigarroa JE, Zahr F. Prevalence and outcomes of mitral stenosis in patients undergoing transcatheter aortic valve replacement: Findings from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry. *JACC Cardiovasc Interv.* 2018;11:693–702. doi: [10.1016/j.jcin.2018.01.245](#)
 32. Cremer PC, Wang TKM, Rodriguez LL, Lindman BR, Zhang Y, Zajarias A, Hahn RT, Lerakis S, Malaisrie SC, Douglas PS, et al. Incidence and clinical significance of worsening tricuspid regurgitation following surgical or transcatheter aortic valve replacement: Analysis from the PARTNER IIA trial. *Circ Cardiovasc Interv.* 2021;14:e010437. DOI: [10.1161/CIRCINTERVENTIONS.120.010437](#)
 33. Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, Wollenweber T, Ahmed N, Thornton GD, Kelion AD, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. *J Am Coll Cardiol.* 2021;77:128–139. doi: [10.1016/j.jacc.2020.11.006](#)
 34. Afzal A, Nisar T, Jamil AK, Kluger AY, Felius J, Hall SA, Kale P. Use of intra-aortic balloon pump in heart failure admissions requiring inotropic support in the United States between 2004–2014. *J Heart Lung Transplant.* 2019;38:S377–S378. doi: [10.1016/j.healun.2019.01.960](#)
 35. Khera R, Cram P, Lu X, Vyas A, Gerke A, Rosenthal GE, Horwitz PA, Girotra S. Trends in the use of percutaneous ventricular assist devices: Analysis of national inpatient sample data, 2007 through 2012. *JAMA Intern Med.* 2015;175:941–950. doi: [10.1001/jamainternmed.2014.7856](#)
 36. Hernandez AF, Greiner MA, Fonarow GC, Hammill BG, Heidenreich PA, Yancy CW, Peterson ED, Curtis LH. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. *JAMA.* 2010;303:1716–1722. doi: [10.1001/jama.2010.533](#)
 37. Castaño A, Narotsky DL, Hamid N, Khaliq OK, Morgenstern R, DeLuca A, Rubin J, Chiuzan C, Nazif T, Vahl T, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. *Eur Heart J.* 2017;38:2879–2887. doi: [10.1093/eurheartj/ehx350](#)
 38. Nazir S, Ahuja KR, Alamir MA. Is the national readmission database the right database to identify valve-in-valve transcatheter aortic valve replacement patients? *Eur Heart J.* 2020;41:4357. doi: [10.1093/eurheartj/ehaa578](#)

SUPPLEMENTAL MATERIAL

Table S1. ICD 10 codes used for the study

Variables	ICD-10-codes
Transcatheter Aortic Valve Implantation	02RF3
Coronary Artery Disease	I251, I257, I258, I259, I255
Congestive heart failure	I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5–I42.9, I43.x, I50.x, P29.0
Peripheral vascular Disease	I70.x, I71.x, I73.1, I73.8, I73.9, I77.1, I79.0, I79.2, K55.1, K55.8, K55.9, Z95.8, Z95.9
Cerebrovascular disease	G45.x, G46.x, H34.0, I60.x–I69.x
Chronic pulmonary disease	I27.8, I27.9, J40.x–J47.x, J60.x–J67.x, J68.4, J70.1, J70.3
Diabetes Mellitus	E10.0, E10.1, E10.6, E10.8, E10.9, E11.0, E11.1, E11.6, E11.8, E11.9, E12.0, E12.1, E12.6, E12.8, E12.9, E13.0, E13.1, E13.6, E13.8, E13.9, E14.0, E14.1, E14.6, E14.8, E14.9
Chronic Kidney Disease	N18
End-Stage Renal Disease	Z992, N186
Pulmonary circulation disorders	I26.x, I27.x, I28.0, I28.8, I28.9
Peripheral vascular disorders	I70.x, I71.x, I73.1, I73.8, I73.9, I77.1, I79.0, I79.2, K55.1, K55.8, K55.9, Z95.8, Z95.9
Hypertension	I10.x
Liver disease	B18.x, I85.x, I86.4, I98.2, K70.x, K71.1, K71.3–K71.5, K71.7, K72.x–K74.x, K76.0, K76.2–K76.9, Z94.4
Coagulopathy	D65–D68.x, D69.1, D69.3–D69.6
Obesity	E66.x
Weight loss	E40.x–E46.x, R63.4, R64
Atrial fibrillation	I48
Mitral stenosis	I342, I1050
Prior MI	I252
Prior CABG	Z951
Prior Pacemaker	Z950
Prior Stroke	I69, Z8673
Prior PCI	Z955

Abbreviations: ICD=International Classification of Disease, MI=Myocardial Infarction, PCI=Percutaneous coronary intervention, CABG=Coronary artery bypass graft surgery

Table S2. Baseline Characteristics of the study population

	Without Readmission (148,329)	30-Day HF Readmission (5962)	P value*	30-day non- HF readmission (13054)	P value†	P value‡
Age (median [IQR])	81(75-86)	83(76-87)	<0.01	82(75-87)	0.06	<0.01
Age Categories			<0.01		0.01	<0.01
<=64	7512(5.1)	239(4.0)		703(5.4)		
65-74	26974(18.2)	1020(17.1)		2279(17.5)		
75-84	62842(42.4)	2321(38.9)		5429(41.6)		
>=85	51001(34.4)	2382(40.0)		4644(35.6)		
Charlson Comorbidity Index (median [IQR])	7(6-8)	8(7-9)	<0.01	7(6-8)	<0.01	<0.01
Charlson Comorbidity Index Score >8	57915(39.0)	3415(57.3)	<0.01	4850(37.2)	<0.01	<0.01
Elective Index Admission	120366(81.4)	4037(68.0)	<0.01	9907(76.2)	<0.01	<0.01
Female Sex	67678(45.6)	2766(46.4)	0.25	6043(46.3)	0.14	0.21
Primary Payer			<0.01		<0.01	<0.01
Medicare	134856(90.9)	5527(92.7)		12006(92.0)		
Medicaid	1588(1.1)	52(0.9)		149(1.1)		
Private Insurance	8613(5.8)	274(4.6)		679(5.2)		
Self-Pay	534(0.4)	22(0.4)		42(0.3)		
Other	2561(1.7)	79(1.3)		168(1.3)		
Others/Missing[#]	177(0.1)	<11(0.18) [§]		<11(<0.08) [§]		
Median Quartile of Income			0.36		0.66	0.55
0-25th Percentile	30144(20.3)	1247(20.9)		2681(20.5)		
25 to 50th Percentile	40254(27.1)	1574(26.4)		3555(27.2)		
50 to 75th Percentile	40177(27.1)	1645(27.6)		3477(26.6)		
75 to 100th Percentile	35869(24.2)	1413(23.7)		3194(24.5)		
Others/Missing[#]	1885(1.3)	84(1.4)		147(1.1)		
Hospital Size			0.21		0.59	0.36
Small	6699(4.5)	243(4.1)		611(4.7)		
Medium	30564(20.6)	1257(21.1)		2658(20.4)		
Large	111066(74.9)	4462(74.8)		9785(75.0)		

Hospital Teaching			0.17		0.06	0.06
Metropolitan Non-Teaching	15961(10.8)	607(10.2)		1426(10.9)		
Metropolitan Teaching	130993(88.3)	5290(88.7)		11480(87.9)		
Non-Metropolitan Hospital	1375(0.9)	65(1.1)		147(1.1)		
Anemias	6034(4.1)	548(9.2)	<0.01	826(6.3)	<0.01	<0.01
Alcohol Use	94(0.1)	1(0.0)	0.16	7(0.1)	0.67	0.34
Hypertension	132235(89.1)	5391(90.4)	<0.01	11311(86.6)	<0.01	<0.01
Diabetes Mellitus	25956(17.5)	929(15.6)	<0.01	2188(16.8)	0.03	<0.01
Coronary Artery Disease	104023(70.1)	4141(69.5)	0.27	8123(62.2)	<0.01	<0.01
Cerebrovascular Disease	16403(11.1)	543(9.1)	<0.01	1819(13.9)	<0.01	<0.01
COPD	42845(28.9)	2162(36.3)	<0.01	3780(29.0)	0.86	<0.01
Pulmonary Circulation Disorder	28272(19.1)	1404(23.6)	<0.01	1518(11.6)	<0.01	<0.01
Obesity	28406(19.2)	945(15.9)	<0.01	1707(13.1)	<0.01	<0.01
Prior MI	18723(12.6)	803(13.5)	0.05	1498(11.5)	<0.01	<0.01
Prior PCI	29895(20.2)	1156(19.4)	0.15	2496(19.1)	0.01	0.01
Prior CABG	27210(18.3)	1123(18.8)	0.34	2167(16.6)	<0.01	<0.01
Preexisting Pacemaker	14949(10.1)	1265(21.2)	<0.01	1992(15.3)	<0.01	<0.01
Pacemaker Implanted During Index Hospitalization	14747(9.9)	831(13.9)	<0.01	1368(10.5)	0.05	<0.01
Complete Heart Block During Index Hospitalization	13648(9.2)	785(13.2)	<0.01	1311(10.0)	0.01	<0.01
Prior ICD	3854(2.6)	13(0.2)	<0.01	4(0.0)	0.11	<0.01
Weight Loss	4576(3.1)	518(8.7)	<0.01	822(6.3)	<0.01	<0.01
Peripheral Vascular Disease	31157(21.0)	935(15.7)	<0.01	1936(14.8)	<0.01	<0.01
Atrial Fibrillation	59545(40.1)	3562(59.7)	<0.01	6065(46.5)	<0.01	<0.01
Liver Disease	4480(3.0)	259(4.3)	<0.01	512(3.9)	<0.01	<0.01
Chronic Kidney Disease	32721(22.1)	2140(35.9)	<0.01	2723(20.9)	<0.01	<0.01

End-Stage Renal Disease	5826(3.9)	402(6.7)	<0.01	1159(8.9)	<0.01	<0.01
Paravalvular Regurgitation	613(0.4)	57(1.0)	<0.01	57(0.4)	0.69	<0.01
Mitral Stenosis	1327(0.9)	84(1.4)	<0.01	109(0.8)	0.49	<0.01
Mitral Regurgitation	10476(7.1)	522(8.8)	<0.01	593(4.5)	<0.01	<0.01
Heart Failure with Reduced EF	18265(12.3)	1550(26.0)	<0.01	1153(8.8)	<0.01	<0.01
Heart Failure with Preserved EF	64057(43.2)	3383(56.7)	<0.01	2884(22.1)	<0.01	<0.01
Length of Stay > 4 days During Index Hospitalization	51076(34.4)	3531(59.2)	<0.01	5905(45.2)	<0.01	<0.01
Non-Home/Facility Discharge During Index Hospitalization	54641(36.8)	112(3363)	<0.01	6141(47.0)	<0.01	<0.01

Abbreviations: HF=Heart Failure, IQR=Interquartile range, MI=Myocardial Infarction, PCI=Percutaneous coronary intervention, CABG=Coronary artery bypass graft surgery, ICD=Implantable cardioverter defibrillator, HF=Heart failure, EF=ejection fraction

* P value compares Index cases that did not get readmitted with index cases that got readmitted for HF

† P value compares Index cases that did not get readmitted with index cases that got readmitted for non-HF causes

‡ P value compares difference among the three group,: 1-Index cases that did not get readmitted 2- index cases that got readmitted for HF, 3: index cases that got readmitted for non-HF causes

§Observations <11 are not reported per HCUP guidelines

|| “Other” variable includes Worker's Compensation and other government programs.

#The missing values were recoded as “Others/Missing”

Descriptive statistics and regression model are based on weighted data.

Table S3. Baseline Characteristics of the patients with and without HF readmissions

	Crude Analysis			1:1 Propensity Matching		
Variables	Without HF Readmission (12,864)	With HF Readmission (5,962)	Standardized Mean Difference	Without HF Readmission (5,962)	With HF Readmission (5,962)	Standardized Mean Difference
Age (median [IQR])	81(75-87)	83(76-87)	0.1091	82(76-87)	82(76-87)	0.0085
Age Categories						
<=64	695(5.4)	239(4.0)		222(3.7)	239(4.0)	
65-74	2263(17.6)	1020(17.1)		949(15.9)	1020(17.1)	
75-84	5361(41.7)	2321(38.9)		2490(41.8)	2321(38.9)	
>=85	4545(35.3)	2382(40.0)		2301(38.6)	2382(40.0)	
Elective Readmission	910(7.1)	0(0.0)	-0.0784	0(0)	0(0)	0.0000
Female Sex	5963(46.4)	2766(46.4)	0.0006	2739(45.9)	2766(46.4)	0.0088
Primary Payer			0.0123			0.0260
Medicare	11825(91.9)	5527(92.7)		5557(93.2)	5527(92.7)	
Medicaid	149(1.2)	52(0.9)		52(0.9)	52(0.9)	
Private Insurance	670(5.2)	274(4.6)		248(4.2)	274(4.6)	
Self-Pay	42(0.3)	22(0.4)		22(0.4)	22(0.4)	
Other[†]	167(1.3)	79(1.3)		78(1.3)	79(1.3)	
Others/Missing[‡]	11(0.1)	<11(<0.2) *		<11(<0.1) *	<11(<0.3) *	
Median Quartile of Income			0.0219			0.0044
0-25th Percentile	2635(20.5)	1247(20.9)		1145(19.2)	1247(20.9)	
25 to 50th Percentile	3497(27.2)	1574(26.4)		1649(27.7)	1574(26.4)	
50 to 75th Percentile	3435(26.7)	1645(27.6)		1606(26.9)	1645(27.6)	
75 to 100th Percentile	3149(24.5)	1413(23.7)		1483(24.9)	1413(23.7)	

Others/Missing[‡]	147(1.1)	84(1.4)		79(1.3)	84(1.4)	
Hospital Size			0.0116			-0.0098
Small	605(4.7)	243(4.1)		262(4.4)	243(4.1)	
Medium	2631(20.5)	1257(21.1)		1188(19.9)	1257(21.1)	
Large	9628(74.8)	4462(74.8)		4512(75.7)	4462(74.8)	
Hospital Teaching			0.0189			-0.0351
Metropolitan Non-Teaching	1396(10.9)	607(10.2)		549(9.2)	607(10.2)	
Metropolitan Teaching	11321(88.0)	5290(88.7)		5338(89.5)	5290(88.7)	
Non-Metropolitan Hospital	147(1.1)	65(1.1)		75(1.3)	65(1.1)	
Anemias	816(6.3)	548(9.2)	0.0989	537(9.0)	548(9.2)	0.0065
Alcohol Use	<11(<0.05)	<11(<0.2)	-0.0207	<11(<0.2)	<11(<0.2)	-0.0246
Hypertension	11138(86.6)	5391(90.4)	0.1303	5397(90.5)	5391(90.4)	-0.0036
Diabetes Mellitus	2157(16.8)	929(15.6)	-0.0328	946(15.9)	929(15.6)	-0.0078
Coronary Artery Disease	7989(62.1)	4141(69.5)	0.1597	4075(68.3)	4141(69.5)	0.0242
Cerebrovascular Disease	1799(14.0)	543(9.1)	-0.1696	558(9.4)	543(9.1)	-0.0089
Chronic Obstructive Pulmonary Disease	3710(28.8)	2162(36.3)	0.1544	2160(36.2)	2162(36.3)	0.0007
Pulmonary Circulation Disorder	1471(11.4)	1404(23.6)	0.2855	1175(19.7)	1404(23.6)	0.0905
Obesity	1676(13.0)	945(15.9)	0.0773	921(15.4)	945(15.9)	0.0112
Prior MI	1473(11.4)	803(13.5)	0.0592	822(13.8)	803(13.5)	-0.0093
Prior PCI	2461(19.1)	1156(19.4)	0.0064	1171(19.6)	1156(19.4)	-0.0066
Prior CABG	2125(16.5)	1123(18.8)	0.0593	1139(19.1)	1123(18.8)	-0.0067
Preexisting Pacemaker	1959(15.2)	1265(21.2)	0.1463	1170(19.6)	1265(21.2)	0.0387

Prior ICD	364(2.8)	296(5.0)	0.0981	295(5.0)	296(5.0)	0.0001
Smoking	474(3.7)	196(3.3)	-0.0220	186(3.1)	196(3.3)	0.0097
Electrolyte Abnormalities	4019(31.2)	2228(37.4)	0.1267	2236(37.5)	2228(37.4)	-0.0028
Lymphoma	110(0.9)	45(0.8)	-0.0114	48(0.8)	45(0.8)	-0.0060
Solid Organ Tumors	535(4.2)	145(2.4)	-0.1123	166(2.8)	145(2.4)	-0.0232
Weight Loss	801(6.2)	518(8.7)	0.0872	486(8.1)	518(8.7)	0.0192
Peripheral Vascular Disease	1893(14.7)	935(15.7)	0.0268	903(15.2)	935(15.7)	0.0146
Atrial Fibrillation	5947(46.2)	3562(59.7)	0.2757	3556(59.6)	3562(59.7)	0.0021
Liver Disease	508(3.9)	259(4.3)	0.0197	236(4.0)	259(4.3)	0.0188
Chronic Kidney Disease	2642(20.5)	2140(35.9)	0.3201	2015(33.8)	2140(35.9)	0.0437
End-Stage Renal Disease	1149(8.9)	402(6.7)	-0.0877	460(7.7)	402(6.7)	-0.0390
Paravalvular Regurgitation	53(0.4)	57(1.0)	0.0561	40(0.7)	57(1.0)	0.0299
Mitral Stenosis	100(0.8)	84(1.4)	0.0537	85(1.4)	84(1.4)	-0.0007
Mitral Regurgitation	563(4.4)	522(8.8)	0.1548	418(7.0)	522(8.8)	0.0616

Abbreviations: IQR=Interquartile range, MI=Myocardial Infarction, PCI=Percutaneous coronary intervention, CABG=Coronary artery bypass graft surgery, ICD=Implantable cardioverter defibrillator, HF=Heart failure, EF=ejection fraction

*Observations <11 are not reported per HCUP guidelines

† “Other” variable includes Worker's Compensation and other government programs.

‡The missing values were recoded as “Others/Missing”

Descriptive statistics and regression model are based on weighted data.

Table S4. Baseline Characteristics of the patients of low volume (<50 TAVRs), medium volume (51-100 TAVRs) and high volume (>100 TAVRs) annual discharge hospitals in 2018

Variables	Low volume (3371)	Medium Volume (9653)	High Volume (21716)	P value
Age (median [IQR])	81(75-86)	81(75-86)	81(75-86)	0.36
Age Categories				0.01
<=64	138(4.1)	502(5.2)	1149(5.3)	
65-74	667(19.8)	1788(18.5)	4033(18.6)	
75-84	1464(43.4)	4241(43.9)	9255(42.6)	
>=85	1102(32.7)	3122(32.3)	7279(33.5)	
Charlson Comorbidity Index (median [IQR])	7(6-8)	7(6-8)	7(6-8)	<0.01
Charlson Index Score >8	1156(34.3)	3441(35.6)	8320(38.3)	<0.01
Elective Index Admission	2923(86.8)	8254(85.6)	17026(78.4)	<0.01
Female Sex	1591(47.2)	4392(45.5)	9923(45.7)	0.21
Primary Payer				<0.01
Medicare	3101(92.0)	8738(90.5)	19512(89.9)	
Medicaid	70(2.1)	105(1.1)	252(1.2)	
Private Insurance	123(3.6)	531(5.5)	1524(7.0)	
Self-Pay	8(0.2)	31(0.3)	74(0.3)	
Other [†]	67(2.0)	246(2.5)	324(1.5)	
Others/Missing [‡]	<11(<0.3) *	<11(<0.01) *	30(0.1)	
Median Quartile of Income				<0.01
0-25 th Percentile	852(25.3)	2204(22.8)	3542(16.3)	
25 to 50 th Percentile	1011(30.0)	2856(29.6)	5109(23.5)	
50 to 75 th Percentile	909(27.0)	2565(26.6)	6013(27.7)	
75 to 100 th Percentile	550(16.3)	1891(19.6)	6807(31.3)	
Others/Missing [‡]	49(1.4)	137(1.4)	245(1.1)	
Hospital Size				<0.01
Small	339(10.1)	925(9.6)	148(0.7)	
Medium	1310(38.9)	1852(19.2)	4474(20.6)	
Large	1722(51.1)	6876(71.2)	17094(78.7)	
Hospital Teaching				<0.01
Metropolitan Non-Teaching	731(21.7)	1603(16.6)	1260(5.8)	
Metropolitan Teaching	2614(77.5)	7878(81.6)	20456(94.2)	
Non-Metropolitan	26(0.8)	172(1.8)	0(0.0)	
Anemias	139(4.1)	413(4.3)	963(4.4)	0.64
Alcohol Use	<11(<0.3)*	<11(<0.1)*	<11(<0.1)*	0.48
Hypertension	3056(90.7)	8650(89.6)	19544(90)	0.21
Diabetes Mellitus	543(16.1)	1395(14.5)	3086(14.2)	0.01
Coronary Artery Disease	2287(67.8)	6467(67.0)	14928(68.7)	0.01

Cerebrovascular Disease	394(11.7)	990(10.3)	2352(10.8)	0.06
COPD	956(28.4)	2754(28.5)	5888(27.1)	0.02
Pulmonary Circulation Disorder	545(16.2)	1536(15.9)	3748(17.3)	0.01
Obesity	675(20.0)	1882(19.5)	4137(19.1)	0.33
Prior MI	428(12.7)	1168(12.1)	2709(12.5)	0.55
Prior PCI	752(22.3)	1867(19.3)	4252(19.6)	<0.01
Prior CABG	631(18.7)	1638(17.0)	3351(15.4)	<0.01
Prior Pacemaker	355(10.5)	1017(10.5)	2295(10.6)	0.91
Prior ICD	85(2.5)	234(2.4)	531(2.4)	0.95
Electrolyte Abnormalities	526(15.6)	1500(15.5)	3645(16.8)	0.01
Lymphoma	25(0.7)	59(0.6)	179(0.8)	0.13
Solid Organ Tumors	75(2.2)	252(2.6)	589(2.7)	0.26
Weight Loss	112(3.3)	288(3.0)	752(3.5)	0.09
Peripheral Vascular Disease	595(17.7)	1735(18.0)	4069(18.7)	0.13
Atrial Fibrillation	1370(40.6)	3840(39.8)	8932(41.1)	0.08
Weight Loss	112(3.3)	288(3.0)	752(3.5)	0.09
Peripheral Vascular Disease	595(17.7)	1735(18.0)	4069(18.7)	0.13
Liver Disease	88(2.6)	309(3.2)	761(3.5)	0.02
Chronic Kidney	648(19.2)	2008(20.8)	4926(22.7)	<0.01
End-Stage Renal	166(4.9)	454(4.7)	939(4.3)	0.14
Paravalvular Regurgitation	16(0.5)	35(0.4)	93(0.4)	0.61
Mitral Stenosis	28(0.8)	89(0.9)	229(1.1)	0.33
Mitral Regurgitation	221(6.6)	586(6.1)	1615(7.4)	<0.01
Heart Failure with Reduced EF	431(12.8)	1169(12.1)	2591(11.9)	0.36
Heart Failure with Preserved EF	1345(39.9)	4039(41.8)	9805(45.2)	<0.01
Length of Stay During Index Hospitalization	877(26.0)	2538(26.3)	6615(30.5)	<0.01
Routine Home Discharge (Index Admission)	2372(70.4)	6868(71.1)	13656(62.9)	<0.01
Non- Home/Facility Discharge (Index Admission)	999(29.6)	2,785(17.6)	8060(37.1)	

Abbreviations: IQR=Interquartile range, MI=Myocardial Infarction, PCI=Percutaneous coronary intervention, CABG=Coronary artery bypass graft surgery, ICD=Implantable cardioverter defibrillator, HF=Heart failure, EF=ejection fraction

*Observations <11 are not reported per HCUP guidelines

† “Other” variable includes Worker's Compensation and other government programs.

‡The missing values were recoded as “Others/Missing”


Descriptive statistics are based on non-weighted data

Table S5. Adjusted odds for all-cause readmissions, HF readmissions, all-cause readmission mortality and HF readmission mortality for High Volume (>100 TAVRs) and Medium Volume Centers (50-100 TAVRs) compared with Low Volume Hospitals (<50 TAVRs)

Variable	All-Cause Readmissions	HF Readmission Mortality	All-Cause Readmission Mortality	HF Readmission Mortality
Medium-Volume Hospitals	1.04(0.92-1.19)	0.94(0.76-1.18)	1.37(0.64-2.90)	1.22(0.38-3.87)
High-Volume Hospitals	0.97(0.86-1.10)	0.83(0.67-1.03)	1.56(0.77-3.21)	1.60(0.54-4.78)


Regression model is based on non-weighted data

Figure S1. Co-Variate Balance Before and After Propensity Matching for patients with and without HF



Abbreviations: MI=Myocardial Infarction, PCI=Percutaneous coronary intervention, CABG=Coronary artery bypass graft surgery, ICD=Implantable cardioverter defibrillator

Figure S2. Cost of Readmission for HF readmissions compared with Non-Heart Failure Readmissions



Abbreviations: HF=Heart Failure